Gut Dysbiosis Associated With Hepatitis C Virus Infection

• Published in: Clinical infectious diseases 2018-08, Vol.67 (6), p.869-877
• Main Authors: Inoue, Takako, Nakayama, Jiro, Moriya, Kei, Kawaratani, Hideto, Momoda, Rie, Ito, Kiyoaki, Iio, Etsuko, Nojiri, Shunsuke, Fujiwara, Kei, Yoneda, Masashi, Yoshiji, Hitoshi, Tanaka, Yasuhito
• Format: Article
• Language: English
• ISSN: 1058-4838; 1537-6591
• DOI: 10.1093/cid/ciy205

In hepatitis C virus infection, the progression of the clinical stage is associated with gut dysbiosis, even if patients are asymptomatic. Overgrowth of viridans streptococci can contribute to the production of ammonia in chronic hepatitis and liver cirrhosis. Abstract Background Little is known about the effect of hepatitis C virus (HCV) infection on gut microbiota and the relationship between alteration of gut microbiota and chronic hepatitis C (CHC) progression. We performed a comparative study of gut microbiota composition between CHC patients and healthy individuals. Methods Fecal samples from 166 CHC patients were compared with those from 23 healthy individuals; the gut microbiota community was analyzed using 16S ribosomal RNA gene sequencing. CHC patients were diagnosed with persistently normal serum alanine aminotransferase without evidence of liver cirrhosis (LC) (PNALT, n = 18), chronic hepatitis (CH, n = 84), LC (n = 40), and hepatocellular carcinoma in LC (n = 24). Results Compared with healthy individuals, bacterial diversity was lower in persons with HCV infection, with a decrease in the order Clostridiales and an increase in Streptococcus and Lactobacillus. Microbiota dysbiosis already appeared in the PNALT stage with the transient increase in Bacteroides and Enterobacteriaceae. Predicted metagenomics of microbial communities showed an increase in the urease gene mainly encoded by viridans streptococci during CHC progression, consistent with a significantly higher fecal pH in CH and LC patients than in healthy individuals or those in the PNALT stage. Conclusions HCV infection is associated with gut dysbiosis, even in patients with mild liver disease. Additionally, overgrowth of viridans streptococci can account for hyperammonemia in CH and LC. Further studies would help to propose a novel treatment strategy because the gut microbiome can be therapeutically altered, potentially reducing the complications of chronic liver disease.